MARCH8 is associated with poor prognosis in non-small cell lung cancers patients
Metrics: PDF 345 views | HTML 1429 views | ?
Jiye Fan1,2, Liying Tian2, Manli Li1, Shu-Hong Huang3, Jing Zhang2 and Baohua Zhao1
1Department of Biochemistry and Molecular Biology, College of Life Science, Hebei Normal University, Shijiazhuang, Hebei 050024, PR China
2Department of Pharmacy, Hebei Chemical and Pharmaceutical College, Shijiazhuang, Hebei 050026, PR China
3Department of Neurobiology, Shandong Provincial Key Laboratory of Mental Disorders, School of Basic Medical Science, Shandong University, Jinan, Shandong 250012, PR China
Baohua Zhao, email: email@example.com
Keywords: MARCH8; ubiquitin ligase; NSCLC; proliferation; apoptosis
Received: May 02, 2017 Accepted: November 03, 2017 Published: November 21, 2017
MARCH8 belongs to a family of membrane-associated RING-CH (MARCH) ubiquitin ligases. The functions of MARCH8 have been thoroughly investigated but its mechanism of action remains unknown. In this study, we detected the expression of MARCH8 protein in NSCLC samples and identified MARCH8 mRNA expression through a TCGA database. In addition, we analyzed the correlation between MARCH8 and the clinical characteristics of NSCLC patients and their prognosis.(www.kmplot.com). The roles of MARCH8 in proliferation, migration, and metastasis were further explored through ectopic expression analysis and western blot analysis; its mechanism of expressionwas also explored. We discovered that MARCH8 was downregulated in NSCLC tissues compared to adjacent normal lung tissues. Overexpression of MARCH8 inhibited NSCLC cell proliferation and metastasis via the PI3K and mTOR signaling pathways; this also increased apoptosis of A549 and H1299 cells. Our results indicated that MARCH8 plays crucial roles in NSCLC against carcinogenesis and progression; therefore, MARCH8 might be a predictive factor and an attractive therapeutic target for NSCLC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.